UniProtKB/Swiss-Prot O14862: Variant p.Glu32Lys

Interferon-inducible protein AIM2
Gene: AIM2
Feedback?

Variant information Variant position:

32 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glutamate (E) to Lysine (K) at position 32 (E32K, p.Glu32Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and acidic (E) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs2276405 [ dbSNP | Ensembl ]

Sequence information Variant position:

32 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

343 The length of the canonical sequence.
Location on the sequence:

TGLDNITDEELDRFKFFLSD E FNIATGKLHTANRIQVATLM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TGLDNITDEELDRFKFFLSDEFNIATGKLHTANRIQVATLM

Mouse                         TGLDHITEEELKRFKYFALTEFQIARSTLDVADRTELADHL

Baker's yeast                 EGVCHDGTPKGRREEIFGLDTY-------------------

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 343	Interferon-inducible protein AIM2
Domain	1 – 87	Pyrin
Mutagenesis	14 – 14	L -> A. Fails to activate interleukin-1 beta production.
Mutagenesis	21 – 21	E -> K. Impaired ability to nucleate with PYCARD/ASC.
Mutagenesis	23 – 23	D -> K. Impaired homooligomerization.
Mutagenesis	27 – 27	F -> G. Abolished ability to homooligomerize.
Mutagenesis	27 – 27	F -> L. Strongly impaired ability to homooligomerize.
Mutagenesis	27 – 27	F -> WY. Impaired ability to homooligomerize.
Mutagenesis	36 – 36	A -> RD. Impaired homooligomerization.
Mutagenesis	46 – 46	I -> D. Impaired homooligomerization.
Mutagenesis	50 – 50	T -> A. Impaired double-stranded DNA (dsDNA)-binding, preventing homooligomerization.
Turn	30 – 32

Literature citations
The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers.
Woerner S.M.; Kloor M.; Schwitalle Y.; Youmans H.; Doeberitz M.K.; Gebert J.; Dihlmann S.;
Genes Chromosomes Cancer 46:1080-1089(2007)
Cited for: ROLE IN COLON CANCER; VARIANTS LYS-32 AND TYR-304;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.